Clinical Trial Update: Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating autologous T cells engineered to express L1CAM-specific CARs for locally advanced, unresectable, or metastatic small cell neuroendocr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Small Cell Neuroendocrine Carcinoma of the Prostate

Drugs mentioned

• Autologous T cells lentivirally transduced to express L1CAM-specific chimeric antigen receptors (L1CAM-CAR T cells) (L1CAM-CAR T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Status: WITHDRAWN